Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

NCT05429905 is registered in ClinicalTrials.gov with KK Women's and Children's Hospital as lead sponsor.

NCT NCT05429905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05429905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
Lead sponsor
KK Women's and Children's Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 18, 2022
Completion date
December 31, 2025
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

car, lymphoblastic leukemia, lymphoblastic leukemia in children, lymphoblastic leukemia, acute adult, lymphoblastic leukemia, acute, childhood